ORIGINAL RESEARCH p v l

Non-small cell lung cancer (NSCLC) accounts for more than 80 % of diagnosed lung cancer cases and is often de-tected at an advanced stage, rendering it extremely difficult to treat with current therapeutic regimes. Lung cancer that is detected in the advanced stage may be treated with molecular-targeted drugs; however, it is commonly treated with chemoradiotherapy [1]. For chemotherapy, the current practice is to deliver several anticancer drugs with different mechanisms of action, thereby reducing the dose of each drug required, thus, decreasing the occurrence of side ef-fects, as well as benefitting from synergistic tumour reduc-tion effects. Thus, combination therapy is commonly used as a treatment regimen for lung cancer. On the other hand, radiotherapy depends on the sensitiv-ity of specific tumour cells to radiation. The effectiveness of * Correspondence: kanno@ka2.so-net.ne.jpKeywords: Tc MIBI; Doxorubicin; Irradiation; MDR; NoAbstrac